Comparison
Liraglutide vs. Thymosin Alpha-1
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Metabolic
Healing
CAS no.
204656-20-2
62304-98-7
Molecular weight
3751 g/mol
3108.32 g/mol
Half-life
13 h
2 h
Sequence
HAEGTFTSDVSSYLEGQAAKEFIAWLVRGRGAc-SDAAVDTSSEITTKDLKEKKEVVEEAENMechanism of action
Liraglutide
Liraglutide is a synthetic GLP-1 analog with 97% sequence identity to human GLP-1. A fatty-acid side chain (C16) on Lys-26 reversibly binds serum albumin and protects against DPP-4 degradation. GLP-1 receptor activation glucose-dependently stimulates insulin secretion, inhibits glucagon secretion, delays gastric emptying and modulates central satiety.
Thymosin Alpha-1
Thymosin Alpha-1 is an N-terminally acetylated peptide originally isolated from the thymus. It modulates T-lymphocyte maturation and function and acts on dendritic cells via Toll-like receptors (TLR9 / TLR2). In preclinical and some clinical studies, increased interferon-gamma responses and altered T-cell subpopulations have been reported.
Evidence base
Highest evidence
Human RCT
Human RCT
Studies
5
2
of which in humans
4
2
Effects recorded
3
3
Open conflicts
0
1
Documented adverse events
1
1